BioCentury
ARTICLE | Clinical News

RHB-102 regulatory update

March 4, 2013 8:00 AM UTC

RedHill said it plans to submit an NDA to FDA in 4Q13 for RHB-102 to prevent nausea and vomiting in cancer patients following its Type B pre-NDA meeting with the agency. Last year, the company reporte...